Clinical Trial Update: Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis [Phase 4]

View source ↗

Summary

Phase 4 biomarker study evaluating Fingolimod (FTY720) in patients with relapsing-remitting multiple sclerosis has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• GILENYA (FINGOLIMOD HCL)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Relapsing-remitting Multiple Sclerosis | Phase 4 | Status: COMPLETED